Bharat bandh evokes good response in Manglauru, Udupi

Belagavi, 13: In a shocking development, Karnataka has reported its first COVID-19 relapse with a 50-year-old Tablighi Jamaat convention attendee in Belagavi testing positive days after being discharged.

The State health officials confirmed that P-298 from Kudachi, who had recovered and was discharged, has suffered a relapse. He has been re-admitted to a designated hospital in Belagavi.

The patient was initially admitted on April 15 and recovered, testing negative twice on April 30 and May 1. The tests were done at the National Institute of Virology (NIV), Bengaluru, and the National Institute of Traditional Medicine (NITM), Belagavi.

Despite recovering, his treatment continued in the ICU for other comorbidities, especially cardiac issues. He was discharged on May 4 and quarantined at an institutional facility in Kudachi.

However, he developed symptoms again and was tested for COVID-19 again on May 5 at NITM, Belagavi. The result came back positive. He was re-admitted to a hospital, and on May 6 a second test was done at the Belagavi Institute of Medical Sciences. Again, he tested positive.

Mangaluru, June 6: Four persons were arrested by the Mulki police today in connection with the murder of Abdul Lateef, a 38-year-old businessman.

The arrested are: Mohammed Hasim (27), Nissar alias Riyaz (33), and Mohammed Razim (24), all residents of Mulki, and Aboobakar Siddique (27), a resident of Udupi.

The weapons and vehicles used for murder have been confiscated. Investigation is in progress to find out the motive behind the murder and the arrest of remaining accused.

Abdul Lateef, his father-in-law Muneer, latter’s son Ijaz and relative Imran were returning from Vijaya Bank at Mulki when a gang of nine miscreants waylaid their car and attacked with sharp weapons.

The gang comprised of Hakeem, Wafa, Asim, Siddique, Nissar, Bava, Farhan, Razeem and Siddiq.  While four of them are arrested, police continued hunt to nab other accused.

Abdul Lateef breathed his last while being taken to hospital. Others are undergoing treatment at a private hospital in Mangaluru.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.